Research map: Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies

Back to the article

Papers in this map

  1. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis · Steven R. Ytterberg · 2022 · 1819 citations · Cited by this paper
  2. Therapeutic role of JAK inhibitors in hepatogastrointestinal diseases · Maged El-Ghannam · 2026 · 1 citation · Cites this paper
  3. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus · 2020 · Related
  4. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials · Silvio Danese · 2022 · 641 citations · Cited by this paper
  5. Safety profile of upadacitinib in inflammatory Bowel disease: a dual-source pharmacovigilance study integrating FAERS signal detection and real-world clinical cohort analysis · Wei Tan · 2026 · Cites this paper
  6. Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-Associated Steatohepatitis · 2026 · Related
  7. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease · Edward V. Loftus · 2023 · 476 citations · Cited by this paper
  8. Bridging the Treatment Access Gap: Janus Kinase Inhibitors as First-line Advanced Therapy for Inflammatory Bowel Disease in Resource-variable Settings · Rowan Bandaranaike · 2026 · Cites this paper
  9. WITHDRAWN: Levels of Vitamin D Are Low Before or After Crohn’s disease Is Established? · 2025 · Related
  10. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications · Mark Russell · 2023 · 154 citations · Cited by this paper
  11. Ginseng-derived extracellular vesicles alleviate ulcerative colitis by regulating macrophage glycolytic reprogramming and H3K18la-mediated epigenetic modification · Yuzhe Zhang · 2026 · Cites this paper
  12. Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-Week Multicenter Study From the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition · 2026 · Related
  13. Venous Thromboembolism Risk With JAK Inhibitors: A Meta‐Analysis · Mark Yates · 2020 · 151 citations · Cited by this paper
  14. Biologics, small molecules, and extraintestinal malignancies in inflammatory bowel disease: practical questions and evidence-based answers · Javier P. Gisbert · 2026 · Cites this paper
  15. Elsewhere in the AGA Journals · 2026 · Related
  16. Venous thromboembolism in inflammatory bowel disease · Kimberly M. Cheng · 2020 · 127 citations · Cited by this paper
  17. Increasing Incidence and Prevalence of Microscopic Colitis in Sweden: A Nationwide Population-Based Cohort Study · 2026 · Related
  18. JAK inhibitors for inflammatory bowel disease: recent advances · Sailish Honap · 2023 · 115 citations · Cited by this paper
  19. Association Between Index Adenomas and Advanced Findings at Third Colonoscopy: Data From the New Hampshire Colonoscopy Registry · 2026 · Related
  20. Janus Kinase Inhibitors and Adverse Events of Acne · Jeremy Martinez · 2023 · 62 citations · Cited by this paper
  21. Mosaicism in Patients With Colorectal Cancer or Polyposis Syndromes: A Systematic Review · 2020 · Related
  22. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register · Yvette Meißner · 2023 · 61 citations · Cited by this paper
  23. Metabolic Dysfunction and Alcohol-Associated Steatotic Liver Disease in Women: Epidemiology, Natural History, and Clinical Outcomes · 2026 · Related
  24. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study · Severine A.R.A. Vermeire · 2023 · 59 citations · Cited by this paper
  25. Long-Term Outcomes After Endoscopic Submucosal Dissection for T1 Colorectal Cancer: A Multicenter Prospective Study · 2026 · Related
  26. Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan · Shintaro Akiyama · 2024 · 42 citations · Cited by this paper
  27. Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study · James Benjamin Galloway · 2020 · 38 citations · Cited by this paper
  28. Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials · Vinod Kumar Reddy Solipuram · 2021 · 35 citations · Cited by this paper
  29. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease · Gerd Rüdiger Burmester · 2025 · 28 citations · Cited by this paper
  30. Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study · Sailish Honap · 2025 · 22 citations · Cited by this paper
  31. Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance · Silvio Danese · 2022 · 21 citations · Cited by this paper
  32. Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases · Dhruv Ahuja · 2025 · 14 citations · Cited by this paper
  33. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis · Cindy C Y Law · 2023 · 8 citations · Cited by this paper
  34. Incidence and Risk Factors for Development of Acne (JAKne) in Patients with Inflammatory Bowel Disease Treated With Upadacitinib · David Choi · 2025 · 5 citations · Cited by this paper
  35. Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease · Severine A.R.A. Vermeire · 2025 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)